Article
Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1R206H Transcript and Inhibit Osteogenic Differentiation.
Nucleic acid therapeutics - 1 Jun 2022
Maruyama Rika, Nguyen Quynh, Roshmi Rohini Roy, Touznik Aleksander, Yokota Toshifumi
Abstract excerpt
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by episodic heterotopic ossification. The median life span of people with this disorder is ∼40 years, and currently, there is no effective treatment available. More than 95% of cases are caused by a recurrent mutation (c.617G>A; R206H) of Activin A receptor, type I (ACVR1)/Activin receptor-like kinase-2 (ALK2), a bone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
